Literature DB >> 7722326

Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils.

H Kita1, R I Abu-Ghazaleh, S Sur, G J Gleich.   

Abstract

Eosinophil granule proteins, such as major basic protein (MBP), eosinophil peroxidase (EPO), and eosinophil cationic protein (ECP), possess a wide range of biologic activities including the ability to activate other cells, such as basophils, neutrophils, and platelets. Here we have analyzed the effects of these proteins on eosinophils themselves. MBP and EPO, at concentrations as low as 0.1 micrograms/ml, induced eosinophil degranulation as measured by release of eosinophil-derived neurotoxin (EDN); in contrast, ECP, at 1 micrograms/ml, was inactive. MBP (10 micrograms/ml) and EPO (0.1 micrograms/ml) induced EDN release comparable with one of the strongest agonists for eosinophils, secretory IgA. Pretreatment of cells with dibutyryl cAMP or cytochalasin B completely abolished the EDN release induced by MBP and EPO, suggesting that the effects of MBP and EPO are not due to cytotoxic lysis of the cells. Degranulation induced by MBP was only partially dependent on calcium, and no elevation of intracellular Ca2+ concentration ([Ca2+]i) was observed in eosinophils stimulated with MBP. MBP stimulated the production, up to eightfold, of IL-8 by eosinophils in a dose-dependent manner. The MBP-stimulated expression of IL-8 mRNA by eosinophils was confirmed by reverse transcription-PCR. The MBP-stimulated production of IL-8 was inhibited by actinomycin D, but not by cyclosporin A. Furthermore, MBP and calcium ionophore ionomycin synergistically induced production of leukotriene C4 from eosinophils. Thus, MBP and EPO may act as autocrine mediators in the pathogenesis of eosinophil-associated diseases, such as bronchial asthma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7722326

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Eosinophil granule-derived major basic protein induces IL-8 expression in human intestinal myofibroblasts.

Authors:  G T Furuta; S J Ackerman; J Varga; A M Spiess; M Y Wang; B K Wershil
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

2.  Selective inflammatory response induced by intratracheal and intravenous administration of poly-L-arginine in guinea pig lungs.

Authors:  D Arseneault; K Maghni; P Sirois
Journal:  Inflammation       Date:  1999-06       Impact factor: 4.092

3.  Increased interleukin-8 release by beta-adrenoceptor activation in human transformed bronchial epithelial cells.

Authors:  A Lindén
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 4.  Eosinophils: multifaceted biological properties and roles in health and disease.

Authors:  Hirohito Kita
Journal:  Immunol Rev       Date:  2011-07       Impact factor: 12.988

5.  A comparison of allergen and polycation induced cutaneous responses in the rabbit.

Authors:  H Jones; W Paul; C P Page
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

6.  Stimulation of P2 purinergic receptors induces the release of eosinophil cationic protein and interleukin-8 from human eosinophils.

Authors:  Marco Idzko; Elisabeth Panther; Hinrich C Bremer; Stephan Sorichter; Werner Luttmann; Christian J Virchow; Francesco Di Virgilio; Yared Herouy; Johannes Norgauer; Davide Ferrari
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

Review 7.  IgE, mast cells, and eosinophils in atopic dermatitis.

Authors:  Fu-Tong Liu; Heidi Goodarzi; Huan-Yuan Chen
Journal:  Clin Rev Allergy Immunol       Date:  2011-12       Impact factor: 8.667

8.  Polarized secretion of interleukin (IL)-6 and IL-8 by human airway epithelia 16HBE14o- cells in response to cationic polypeptide challenge.

Authors:  Alison Wai-ming Chow; Jocelyn Feng-ting Liang; Janice Siu-chong Wong; Yan Fu; Nelson Leung-sang Tang; Wing-hung Ko
Journal:  PLoS One       Date:  2010-08-12       Impact factor: 3.240

9.  Eosinophil ribonucleases and their cutaneous lesion-forming activity.

Authors:  Douglas A Plager; Mark D P Davis; Amy G Andrews; Michael J Coenen; Terry J George; Gerald J Gleich; Kristin M Leiferman
Journal:  J Immunol       Date:  2009-08-28       Impact factor: 5.422

10.  Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis.

Authors:  Angélica T Vieira; Caio T Fagundes; Ana Leticia Alessandri; Marina G M Castor; Rodrigo Guabiraba; Valdinéria O Borges; Kátia Daniella Silveira; Erica L M Vieira; Juliana L Gonçalves; Tarcilia A Silva; Maud Deruaz; Amanda E I Proudfoot; Lirlândia P Sousa; Mauro M Teixeira
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.